Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Tesla UK Sales Slide as Competition Intensifies, While BYD Surges in Electric Vehicle Market 
SGH’s A$13.15 Billion BlueScope Bid Sparks Steel Sector Shake-Up and Share Price Surge 
Samsung Electronics Poised for Massive Q4 Profit Surge on Soaring Memory Chip Prices 
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
Cathay Pacific Shares in Focus as Air China Plans Major Stake Reduction 
Intel Unveils Panther Lake AI Laptop Chips at CES 2025, Marking Major 18A Manufacturing Milestone 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Samsung to Double AI-Powered Mobile Devices with Google Gemini in Global AI Race 
Nvidia Unveils Rubin Platform to Power Next Wave of AI Infrastructure 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Saks Global Enterprises Seeks $1 Billion Loan Amid Possible Chapter 11 Bankruptcy Filing 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Chinese EV Stocks Slide as December Sales Growth Slows, Raising Demand Concerns 
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its third quarter 2017 financial results will be reported on Tuesday, November 7, 2017.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
